Randomised controlled trial of carbamazepine assisted detoxification in patients with benzodiazepine dependence

ISRCTN ISRCTN44535130
DOI https://doi.org/10.1186/ISRCTN44535130
Secondary identifying numbers N0133160479
Submission date
30/09/2005
Registration date
30/09/2005
Last edited
27/10/2015
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Chris Daly
Scientific

Wentworth House
Mental Health Services of Salford
8 Westminster Road
Eccles
Salford
M30 9HF
United Kingdom

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleRandomised controlled trial of carbamazepine assisted detoxification in patients with benzodiazepine dependence
Study objectives1. Carbamazepine minimizes severity and incidence of benzodiazepine withdrawal symptoms.
2. Carbamazepine assisted detoxification increases the abstinence rates of benzodiazopines in short term.
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedMental and Behavioural Disorders: Addiction
Intervention1. Carbamazepine assisted benzodiazepine detox for 2 weeks
2. Traditional gradual withdrawal of diazepam

Observers will be blinded from allocation of groups. Analysis of Variance (ANOVA) will be used to compare 2 groups.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Carbamazepine
Primary outcome measure1. Benzodiazepine withdrawal symptom questionnaire (30 items)
2. Hamilton Depression Rating Scale (17 items) HAM-D)
3. Hamilton Anxiety Rating Scale (HAM-A)
4. Abstinence rates from benzodiazepines

Patients will be assessed at 3 points:
1. Baseline
2. 1 week after starting the detoxification
3. 2 weeks (end of detoxification)

Follow-up interview or phone call will be made 4 weeks after discharge asking if patient are abstinent from benzodiazepines.
Secondary outcome measuresNot provided at time of registration
Overall study start date21/09/2004
Completion date30/05/2006

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
Upper age limit65 Years
SexBoth
Target number of participantsTarget total for recruitment: 50
Key inclusion criteriaPatients (18-65 years) who are admitted to Wentworth House or Kenyon House in-patient units, and are using daily doses of benzodiazepine for at least 3 months.
Key exclusion criteria1. Significant psychiatric disorders (by ICD 10)
2. History of or current liver failure
3. Current Alanine Transaminase ( ALT) > or equal 150 IU/l in serum LFT
4. Current suicidal ideation
5. Patients who are already on Carbamazepine before referral for In Patient treatment.
Date of first enrolment21/09/2004
Date of final enrolment30/05/2006

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Wentworth House
Salford
M30 9HF
United Kingdom

Sponsor information

Department of Health
Government

Richmond House
79 Whitehall
London
SW1A 2NL
United Kingdom

Phone +44 (0)20 7307 2622
Email dhmail@doh.gsi.org.uk
Website http://www.dh.gov.uk/Home/fs/en

Funders

Funder type

Government

Bolton, Salford and Trafford Mental Health NHS Trust (UK), NHS R&D Support Funding

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan